Publication

Article

CURE

Summer 2009
Volume8
Issue 2

Interventions Needed to Get Survivors Moving

Author(s):

Researchers identify what survivors need to get physically active.

Researchers knew up to half of adult survivors of childhood cancer don’t exercise, and now they have a better idea why. Identifying aspects that influence survivors’ participation in physical activity was the aim of a study published in February in Cancer.

As part of the Childhood Cancer Survivor Study, this ancillary study found the modifiable predictors of physical activity to be emotions such as feeling unhappy, fear of recurrence or future health issues, motivation, and encouraging interaction between the survivor and his or her physician. In creating exercise interventions, consideration of these factors have the potential to support positive behavior change in childhood cancer survivors, concluded the researchers. Exercise during and after treatment is particularly important for this group because it may relieve or prevent some of therapy’s long-term effects, such as pain, fatigue, osteoporosis, and cardiomyopathy.

Lead researcher Cheryl Cox, PhD, of St. Jude Children’s Research Hospital in Memphis, says while studies are ongoing to determine the specific exercises that may help childhood cancer survivors, a combination of aerobic, flexibility, and strengthening exercises would be beneficial. “Obviously, the type and extent/frequency would need to be individualized to the survivor,” Cox says. “What might work very well for one survivor might be detrimental to another.”

The study also found that health care providers should use gender-tailored intervention strategies to support physical activity in childhood cancer survivors. For example, men preferred information conveyed by print, video, or web-based media, while women were more responsive to direct contact with their primary care physician.

Cox says St. Jude is about to launch a study that introduces individualized exercises seven to 10 days after diagnosis in childhood cancer patients. “It is our fervent hope that during treatment we can lay the foundation for pursuing physical activity lifelong,” she says.

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Related Content